AYTU BIOPHARMA, INC (AYTU)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 06-30. Amounts in USD.

Revenue TTM

0 40M 80M 120M Q4 '21: 65.6M Q1 '22: 74M Q2 '22: 82M Q3 '22: 92.7M Q4 '22: 96.7M Q1 '23: 102.4M Q2 '23: 105.6M Q3 '23: 104.1M Q4 '23: 107.4M Q1 '24: 97.6M Q2 '24: 90M Q3 '24: 81.3M Q4 '24: 65.2M Q1 '25: 63.9M Q2 '25: 61.4M Q3 '25: 65.8M Q4 '25: 66.4M Q1 '26: 63.7M Q2 '26: 62.6M Q3 '26: 56.6M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit TTM

0 25M 50M 75M Q4 '21: 29.2M Q1 '22: 32.2M Q2 '22: 35.6M Q3 '22: 48.7M Q4 '22: 52.3M Q1 '23: 57.9M Q2 '23: 62.9M Q3 '23: 62.9M Q4 '23: 66.6M Q1 '24: 61.6M Q2 '24: 58.9M Q3 '24: 56.6M Q4 '24: 49.1M Q1 '25: 48M Q2 '25: 44.2M Q3 '25: 46.6M Q4 '25: 45.8M Q1 '26: 43M Q2 '26: 41.9M Q3 '26: 36.7M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q4 '21: -58.9M Q1 '22: -83M Q2 '22: -88.7M Q3 '22: -116.5M Q4 '22: -109.4M Q1 '23: -83.5M Q2 '23: -79M Q3 '23: -34.2M Q4 '23: -17.1M Q1 '24: -16.1M Q2 '24: -6.1M Q3 '24: 851K Q4 '24: -1.6M Q1 '25: -1.7M Q2 '25: -6.5M Q3 '25: -2.5M Q4 '25: -7.8M Q1 '26: -8.4M Q2 '26: -8.7M Q3 '26: -15.2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q4 '21: -58.3M Q1 '22: -81.8M Q2 '22: -83.9M Q3 '22: -111.7M Q4 '22: -108.8M Q1 '23: -81.6M Q2 '23: -76.8M Q3 '23: -30.7M Q4 '23: -17.1M Q1 '24: -24.5M Q2 '24: -18M Q3 '24: -13.7M Q4 '24: -15.8M Q1 '25: -6.2M Q2 '25: -5.2M Q3 '25: 1.6M Q4 '25: -13.6M Q1 '26: -13.1M Q2 '26: -24.4M Q3 '26: -34.1M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue TTM

0 20M 40M 60M Q4 '21: 36.4M Q1 '22: 41.8M Q2 '22: 46.4M Q3 '22: 44M Q4 '22: 44.4M Q1 '23: 44.6M Q2 '23: 42.7M Q3 '23: 41.2M Q4 '23: 40.8M Q1 '24: 35.9M Q2 '24: 31.1M Q3 '24: 24.8M Q4 '24: 16.1M Q1 '25: 15.9M Q2 '25: 17.2M Q3 '25: 19.2M Q4 '25: 20.6M Q1 '26: 20.7M Q2 '26: 20.8M Q3 '26: 19.9M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q4 '21: 2.5M Q1 '22: 6.7M Q2 '22: 810K Q3 '22: -28M Q4 '22: -28.8M Q1 '23: -34.2M Q2 '23: -27.8M Q3 '23: -21.6M Q4 '23: -5.1M Q1 '24: 3.8M Q2 '24: 6.1M Q3 '24: 8.8M Q4 '24: -1.4M Q1 '25: -2.4M Q2 '25: 673K Q3 '25: -5.5M Q4 '25: -1.9M Q1 '26: -1.4M Q2 '26: -595K Q3 '26: 1.7M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q3 '14: -35.7K Q4 '14: -34.8K Q2 '16: -8.8M Q3 '16: -10M Q4 '16: -10.9M Q1 '17: -14.1M Q2 '17: -13.4M Q3 '17: -13.3M Q4 '17: -13.9M Q2 '19: -15.7M Q3 '19: -15M Q4 '19: -13.9M Q1 '20: -14.1M Q2 '20: -20.4M Q3 '20: 2.2M Q4 '20: -2.1M Q4 '25: -2.2M Q1 '26: -1.5M Q2 '26: -698K Q3 '26: 1.6M Q4 '14 Q4 '16 Q3 '17 Q3 '19 Q2 '20 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 7M 14M 21M Q1 '21: 12.2M Q2 '21: 13.3M Q3 '21: 18.1M Q1 '22: 1.3M Q2 '22: 1.3M Q3 '22: 1.5M Q1 '23: 2.5M Q2 '23: 3.1M Q3 '23: 3.7M Q1 '24: 5.5M Q2 '24: 5.5M Q3 '24: 5.5M Q1 '25: 9.1M Q2 '25: 8.5M Q3 '25: 8.2M Q1 '26: 19.5M Q2 '26: 10M Q3 '26: 10.5M Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-75.00 -50.00 -25.00 0.00 25.00 50.00 75.00 Q4 '21: -3.25 Q1 '22: -24.66 Q2 '22: -32.68 Q3 '22: -67.17 Q4 '22: -72.28 Q1 '23: -50.80 Q2 '23: -44.21 Q3 '23: -10.24 Q4 '23: -4.76 Q1 '24: -5.96 Q2 '24: -3.85 Q3 '24: -2.44 Q4 '24: -2.86 Q1 '25: -1.53 Q2 '25: -1.75 Q3 '25: -1.02 Q4 '25: -3.38 Q1 '26: -3.31 Q2 '26: -4.10 Q3 '26: -4.84 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.